drugset / Trial / NCT02832128

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

NCT02832128 ↗

Phase 2 Completed 15 enrolled Autifony Therapeutics Limited
RandomizedCrossoverQuadruple-blindTreatment

Summary

The objective of this pilot study is to explore whether repeat doses of AUT00063 can provide an indication of improvement in performance of tests across a battery of speech and hearing assessments in cochlear implant users.

Timeline

Start
2016-05
Primary completion
2017-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AUT00063 Unknown 800 mg Oral

Indications